OSLO, NORWAY – 28 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the award of an important patent (US20200400666) by the United States Patent and Trademark Office (USPTO) entitled “A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT”. The invention covered provides a diagnostic method to be used to determine the likelihood that a patient with Irritable Bowel Syndrome (IBS) will respond to treatment with a low-FODMAP diet or Faecal Microbiota Transplant (FMT).
The patent family claims priority from 15th October 2016 and hence will be in force until 2037 and is part of the Company’s active patent strategy covering all major geographical markets. It confirms the Company’s strategic commitment to developing innovative non-invasive diagnostic tools useful for patients, doctors and healthcare providers.
CEO Ronny Hermansen comments:
“We are delighted to announce that our patent “A companion diagnostic method for use in the treatment of irritable bowel syndrome (IBS) with dietary interventions or faecal microbiota transplant” was allowed for grant for dietary intervention with low-FODMAP diets in the US. A divisional application from the same family covering Fecal Microbiota Transplant (FMT) was previously granted in October 2020. IBS is a condition that affects 10-15% of the population in the US and EU and it is vital that these patients receive better diagnostic tools that can help optimize treatment regimes. The approval further strengthens our intellectual property portfolio and is an important milestone in GA´s focus on developing diagnostics that use gut microbiota signatures to predict treatment outcomes”.
For more information on Genetic Analysis, please contact:
Ronny Hermansen, CEO
This information is such information that Genetic Analysis AS is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 28 October 2021.
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com